Clinical advisory : routine screening for Hepatitis C by Massachusetts. Department of Public Health.
CLINICAL ADVISORY: 
ROUTINE SCREENING FOR HEPATITIS C  
Updated: October 2014 
 
 
 
 
 
 
 
 
 
 
This Clinical Advisory provides practice guidelines to support implementation of the 
recommendation along with background information about the impact of HCV in the 
Commonwealth, the basis for the current MDPH recommendation, and sources of additional 
information.  
Practice Guidelines 
The MDPH recommends that health care providers:  
1. Test all patients born between 1945 and 1965 for HCV, at least once, regardless of HCV 
risk history. 
2. Ask all patients whether they have ever injected illicit drugs.  Recommend HCV testing 
to individuals who have injected illicit drugs, even if only once or in the distant past.  
3. Test all HIV-infected patients for HCV at initial evaluation.1,2   
a. HIV-infected patients should also be tested for HCV if liver function tests indicate 
abnormalities that could be caused by HCV infection.  
b. HIV-infected men who have sex with men (MSM), including those who have 
previously undergone successful treatment for or spontaneously cleared HCV 
infection, should be routinely screened for HCV to identify reinfection with 
HCV.3,4,5   
4. Assess all patients for other HCV risks.  Recommend HCV testing for individuals who: 
 Have persistently elevated alanine aminotransferase (ALT) levels; 
The Commonwealth of Massachusetts 
Executive Office of Health and Human Services 
Department of Public Health 
250 Washington Street, Boston, MA 02108-4619 
 
Tel: 617-624-5200 
Fax: 617-624-5206 
www.mass.gov/dph 
 
DEVAL L. PATRICK 
GOVERNOR 
JOHN W. POLANOWICZ 
SECRETARY 
CHERYL BARTLETT, RN 
COMMISSIONER 
 
The Massachusetts Department of Public Health (MDPH) endorses 
recommendations of the Centers for Disease Control and Prevention, and the 
U.S. Preventive Services Task Force and recommends routine hepatitis C virus 
(HCV) screening for individuals at risk for HCV and for individuals born between 
1945 and 1965, due to the significant individual and public health benefits 
associated with knowledge of HCV status and prompt linkage to medical care 
and preventive services. Pursuant to M.G.L. c. 111, § 4M as amended by Section 
138 of Chapter 165 of the Acts of 2014, primary care providers shall offer 
hepatitis C testing to individuals born between 1945 and 1965.   
 
 
 Received blood products for clotting factor replacement prior to 1987; 
 Received blood transfusions or organ transplant prior to July, 1992; 
 Have ever been on long-term hemodialysis; 
 Are children born to mothers with HCV infection; 
 Are health care workers and others who have had mucosal or percutaneous exposure 
to HCV-infected blood.   
5. For patients who test positive for HCV antibody, order an HCV nucleic acid test (NAT) to 
confirm current HCV infection.6 
6. For patients with current HCV infection: 
a. Promptly evaluate for treatment and/or provide treatment referrals;  
b. Provide counseling about how to maintain liver health and how to prevent 
secondary transmission; 
c. Recommend vaccination for hepatitis A and hepatitis B, if appropriate;  
d. Refer for drug and alcohol treatment, if appropriate.  
7. Patients who currently inject drugs, regardless of current HCV infection status, should 
be: 
a. Tested for HIV infection; 
b. Provided with access to sterile injection equipment and naloxone to prevent 
overdose; 
c. Referred for opioid replacement therapy and/or other drug treatment, if 
appropriate.  
8. Complete and submit to MDPH a case report form for each newly identified case of HCV 
infection. HCV infection is reportable pursuant to 105 CMR 300.000 Reportable 
Diseases, Surveillance, and Isolation and Quarantine Requirements. Case report forms 
will be sent by MDPH to providers automatically based on receipt of laboratory test 
results indicating HCV infection.   
Background  
Hepatitis C virus (HCV) infection is a serious public health problem. The Centers for Disease 
Control and Prevention (CDC) estimates that there are at least 2.7 to 3.9 million persons in the 
U.S. living with HCV, up to 75 percent of whom are not aware of their infection. Approximately 
75 to 85 percent of people exposed to HCV will develop chronic infection, 60 to 70 percent will 
develop chronic liver disease, five to 20 percent will develop cirrhosis over the course of their 
chronic infection, and between one and five percent will die of complications from HCV infection, 
including hepatocellular carcinoma.7 There is no vaccine that protects against HCV infection. 
In Massachusetts, between 7,000 and 10,000 newly diagnosed cases of HCV infection are 
reported annually to the MDPH. Based on MDPH surveillance data, it is estimated that 
approximately 200,000 people in Massachusetts are living with HCV infection. There has been a 
significant increase in HCV infection among young people who inject drugs. Between 2002 and 
2013 annual reports of new HCV diagnoses in individuals between the ages of 15 and 29 years 
increased by 137 percent. MDPH estimates that there are approximately 8,500 new infections in 
this age group annually and transmission is attributable primarily to injecting heroin and/or 
prescription opiates.  
HCV infection is a major cause of liver disease, including cirrhosis and liver cancer. In the U.S. 
rates of liver cancer and deaths due to HCV infection continue to increase and have now 
exceeded those of HIV infection, with approximately 15,000 HCV-associated deaths occurring in 
the U.S. in 2007. 8,9,10  In Massachusetts, among those with known HCV infection who died 
through 2009, the median interval between HCV infection diagnosis and death was three years, 
and the median age of death attributable to HCV infection was 54 years, suggestive of late 
diagnosis.  
Basis for Current Recommendation 
In July 2014, the M.G.L. c. 111, § 4M was amended by Section 138 of Chapter 165 of the Acts 
of 2014 to require primary care providers to offer testing for hepatitis C infection to patients born 
between 1945 and 1965 unless medically inadvisable, the patient lacks capacity to consent to 
testing, or the patient has previously been offered or been tested for hepatitis C infection.   
In August 2012, the Centers for Disease Control and Prevention (CDC) issued 
Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons 
Born During 1945–1965 recommending one-time testing, regardless of HCV risk, for persons 
born during 1945 to 1965.11  These recommendations complement and do not replace previous 
recommendations for risk-based testing.   
In its Recommendations for Prevention and Control of Hepatitis C Virus Infection and HCV 
Related Chronic Disease the CDC recommends routine testing for HCV based on risk for 
infection.12  Individuals at risk for HCV infection include those who inject(ed) drugs, received 
long-term hemodialysis, received clotting factor prior to 1987, or were recipients of transfusions 
or organ transplants prior to 1992.   
On June 25, 2013, the US Preventive Services Task Force (USPSTF) issued a 
recommendation on HCV screening.13 The USPSTF recommends screening for HCV infection 
for persons at risk of infection and also recommends one-time screening for HCV infection for 
all adults born between 1945 and 1965.  The USPSTF assigned a B grade to this 
recommendation. Assignment of a “B” grade by the USPSTF means that providers will have 
increased opportunities to seek third-party reimbursement for these services because, 
beginning in 2014, HCV screening will be covered by most private and public health insurance. 
The Affordable Care Act (ACA) requires that private insurance plans cover USPSTF preventive 
care recommendations that receive an “A” or ”B” grade, and to do so without cost sharing.   
Benefits of HCV Testing, Care, and Treatment 
Testing is the critical first step to linking individuals with HCV infection with preventive care and 
treatment that will improve their health, delay disease progression, and reduce mortality. 
Screening individuals born between 1945 and 1965 can identify individuals infected with HCV 
who would otherwise not be tested.  
Antiviral treatment is only indicated for persons with current HCV infection. Therefore it is 
essential that testing be performed that distinguishes patients with current HCV infection from 
those who have previously undergone successful treatment or have spontaneously cleared 
HCV infection.  NAT testing should be performed to confirm current infection for all individuals 
receiving positive HCV antibody test results.   
Provision of counseling about how to maintain liver health (e.g. by limiting alcohol or other drug 
consumption) and prevent secondary transmission (e.g. by not sharing syringes, tattoo, or body 
piercing equipment and by avoiding blood exposure during sexual contact) and referral to other 
preventive services, such as hepatitis A and B vaccines, and drug or alcohol treatment can 
improve health outcomes for individuals living with HCV infection.  Provision of risk reduction 
supplies, such as sterile injection equipment can support behavior change, as can access to 
opioid replacement therapies.  
The American Association for the Study of Liver Diseases and the Infectious Diseases Society 
of American has updated practice guidelines for testing, management, and treatment of HCV 
infection: Recommendations for Testing, Managing, and Treating Hepatitis C. With proper 
support, individuals actively using drugs can be treated for HCV infection and achieve sustained 
virologic response.14  Treatment for HCV infection is evolving rapidly and newer treatment 
regimens promise treatment of shorter duration, easier drug administration, better patient 
tolerability, and improved efficacy.  The advent of these improved therapies reinforces the 
importance of identifying previously undetected cases of HCV infection. 
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RESOURCES 
For Health Care Professionals:  
  From the Massachusetts Department of Public Health: 
Hepatitis C Resources for Health Care Providers 
A resource guide for medical providers, and brochures, factsheets and educational materials for 
patients are available for download.  
  From the CDC:  
Hepatitis C Information for the Health Professional  
Information regarding the epidemiology of HCV, testing and diagnosis, and medical 
management of HCV is available. Screening and treatment guidelines can be downloaded.  
Links to additional resources and information for patients is also available.   
Hepatitis Web Study 
This site provides information regarding the diagnosis and management of viral hepatitis for 
health care workers involved with the care of patients at risk for infection with hepatitis. 
Interactive case-based study modules with free CE credits are features. Slide presentations are 
available for download.  
National Training Center for Integrated Hepatitis HIV/STD Prevention Services 
The National Training Center provides training to workers in community based organizations 
and clinics on hepatitis prevention, diagnosis, management, treatment and integration.  Video 
training and links to other training and educational resources are available.   
  From the American Association for the Study of Liver Diseases :  
Diagnosis, Treatment and Management of Chronic Hepatitis C  
The AASLD publishes practice guidelines for the diagnosis, treatment and management of 
hepatitis C infection.  AASLD publishes tools for clinicians including “GUIDELINES Pocket 
Cards” which present guidelines information concisely.   Training, certification and CME 
opportunities are also available.  
For the Public  
  From the Massachusetts Department of Public Health:  
Hepatitis C Information and Resources 
Fact sheets and educational brochures published in several languages are available for 
download.  A directory of MDPH-supported hepatitis C screening, care and support services is 
available as well as links to other resources and support organizations.   
Information about hepatitis C and service referrals can also be obtained by contacting the 
Massachusetts Hepatitis C Hotline at1-888-443-HepC (4372) 
  From the CDC:  
Hepatitis C Information for the Public 
Information about the epidemiology, transmission and prevention of hepatitis C is available. The 
site also provides links to patient information resources and educational materials. 
 
